Novartis discontinues development of XOMA-licensed NIS793 anti-TGFß antibody

XOMA Royalty Corp

On Aug 25, 2023, Novartis notified XOMA it will stop development of NIS793 (anti-TGFß monoclonal antibody).
Novartis will cease enrolling patients in remaining active TGFß clinical studies and collect final data.
XOMA licensed NIS793 to Novartis in September 2015; no milestones or royalties mentioned in the filing.
NIS793 is investigational; efficacy/safety not established and no guarantee of commercial availability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.